Previous studies have demonstrated that the risk of hyperkalemia increases in patients with low eGFR, particularly with higher doses of spironolactone or the concurrent use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers [29, 30]. The gene discussed is ACE; the disease is Hyperkalemia.